Stock Snapshot
Price Performance
Recommendation Rationale
Moderate growth outlook supported by specialty product focus and strategic acquisitions, tempered by margin pressures and execution risks.
Basis of our Recommendation
Sun Pharmaceutical Industries is positioned for moderate growth driven by its strategic focus on specialty medicines and strong domestic sales. However, the company faces margin pressures due to rising costs and execution risks associated with its recent acquisition of Organon, which is expected to enhance revenue but also presents integration challenges.
Why We Like This Stock
- Strong growth driven by transition to specialty medicines and successful product launches
- Strategic acquisition of Organon expected to significantly boost revenue growth
- Positive market perception and valuation outlook due to branded business performance
Things To Watch Out For
- Margin pressures arising from rising costs
- Execution risks and integration challenges related to the Organon acquisition
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 48,497 | 52,578 | 58,462 | 64,201 | 70,920 |
| Profit Before Tax (Cr.) | 11,592 | 14,446 | 16,426 | 17,847 | 19,986 |
| PBT Margin | 23.9% | 27.5% | 28.1% | 27.8% | 28.2% |
| Net Profit (Cr.) | 9,474 | 11,870 | 12,124 | 13,078 | 14,645 |
| EPS | 39.4 | 49.3 | 50.4 | 54.5 | 61.0 |
Company Overview
Show Company Profile
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, urology, dermatology, respiratory, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. It exports its products to approximately 90 countries across Asia, North America, Europe, Africa, South America, and Australia. Sun Pharmaceutical Industries Limited was founded in 1983 and is headquartered in Mumbai, India.